A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors
The trial was registered at ClinicalTrials.gov with identifier no. NCT04742036. Date of registration: February 4, 2021.
Authors
- Yuxin Mu (ORCID: https://orcid.org/0000-0002-8465-6933)
- Yan Sun (ORCID: https://orcid.org/0000-0001-8525-7814)
- Marie Cullberg (ORCID: https://orcid.org/0000-0003-1697-972X)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-9877-1601)
- Ning Chris Chen (ORCID: https://orcid.org/0000-0003-2897-3042)
- Ling Zhang (ORCID: https://orcid.org/0009-0000-1628-3867)
- Yiqun Du (ORCID: https://orcid.org/0000-0002-2870-6510)
- Xichun Hu (ORCID: https://orcid.org/0000-0002-9892-699X)
- Yanchun Meng
- Xiaojun Liu (ORCID: https://orcid.org/0009-0009-8244-8194)
- E. Fan
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12885-025-14982-4
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Astex Pharmaceuticals